

May 22, 2015

VIA ELECTRONIC PORTAL

Mr. Christopher J. Kirkpatrick Office of the Secretariat Commodity Futures Trading Commission Three Lafayette Centre 1155 21st Street, N.W. Washington, DC 20581

Re: FOIA Confidential Treatment Request

Dear Mr. Kirkpatrick:

By electronic portal dated May 22, 2015, New York Mercantile Exchange, Inc. ("NYMEX" or "Exchange"), a registered designated contract market, provided certain documents to the Commodity Futures Trading Commission ("CFTC" or "Commission"), including the Exchange's methodology of deliverable supply and analysis of the underlying physically-delivered Light Sweet Crude Oil Futures contract relative to the Crude Oil Bullet Futures and associated contracts (the "Confidential Information"). The Confidential Information contains confidential and proprietary commercial information that could, if disclosed to the public, cause substantial harm to the competitive position of the Exchanges.

Pursuant to Sections 8 and 8(a) of the Commodity Exchange Act ("CEA"), as amended, and Commission Regulation 145.9(d), the Exchange requests confidential treatment of the Confidential Information on the grounds that the Confidential Information contains confidential commercial information of the submitter. Pursuant to Commission Regulation 145.9(d)(5), the Exchange requests that confidential treatment be maintained for the Confidential Information <u>until further notice</u>. We also request that the Commission notify the undersigned immediately after receiving any FOIA request for the Confidential Information or any other court order, subpoena or summons for same. Finally, we request that we be notified in the event the Commission intends to disclose the Confidential Information to Congress or to any other governmental agency or unit pursuant to Section 8 of the CEA. The Exchange does not waive its notification rights under Section 8(f) of the CEA with respect to any subpoena or summons for the Confidential Information.

Please contact the undersigned at (212) 299-2200 should you have any questions concerning this letter.

Sincerely,

/s/ Christopher Bowen Managing Director and Chief Regulatory Counsel